Modality
ADC
MOA
MALT1i
Target
GLP-1R
Pathway
NF-κB
Asthma
Development Pipeline
Preclinical
~May 2022
→ ~Aug 2023
Phase 1
~Nov 2023
→ ~Feb 2025
Phase 2
May 2025
→ Jan 2030
Phase 2Current
NCT08438714
1,491 pts·Asthma
2025-05→2030-01·Active
1,491 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-103.8y awayPh3 Readout· Asthma
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P2/3
Active
Catalysts
Ph3 Readout
2030-01-10 · 3.8y away
Asthma
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08438714 | Phase 2/3 | Asthma | Active | 1491 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R |